175 related articles for article (PubMed ID: 29749405)
21. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
24. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
[TBL] [Abstract][Full Text] [Related]
25. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
26. Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro.
Banerjee J; Al-Wadei HA; Al-Wadei MH; Dagnon K; Schuller HM
BMC Cancer; 2014 Sep; 14():725. PubMed ID: 25260978
[TBL] [Abstract][Full Text] [Related]
27. Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.
Qian Y; Yang B; Xiong Y; Gu M
Oncol Rep; 2016 Sep; 36(3):1517-25. PubMed ID: 27459907
[TBL] [Abstract][Full Text] [Related]
28. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Yu S; Wang M; Zhang H; Guo X; Qin R
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
[TBL] [Abstract][Full Text] [Related]
29. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
30. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
[TBL] [Abstract][Full Text] [Related]
31. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z
J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
[TBL] [Abstract][Full Text] [Related]
34. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
Yao N; Chen Q; Shi W; Tang L; Fu Y
Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
[TBL] [Abstract][Full Text] [Related]
35. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
[TBL] [Abstract][Full Text] [Related]
36. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
[TBL] [Abstract][Full Text] [Related]
37. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
38. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
40. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J
Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
